Prior authorization on medications prescribed for antineoplastic cancer treatment prohibition; prior authorization denials based on timing of the provided health care service prohibition; expedited prior authorization review for prescriptions that have previously been authorized or covered requirement

This bill prohibits health insurance plans from requiring prior authorization (insurance approval) for antineoplastic cancer treatments (except for medications themselves), directly affecting cancer patients and their insurers. It also bans denials of coverage based solely on when a healthcare service was provided. Additionally, the bill mandates expedited review for prescriptions that were previously approved or covered for the same patient. These changes aim to reduce delays in accessing critical cancer care by streamlining the insurance approval process. The provisions apply to health benefit plans offered on or after January 1, 2026.